Hello All,
As many of you know the GiACTA (Tocilizumab) clinical trials were finalized in 2016 and the drug was approved in May of 2017 for Giant Cell Arteritis only. After much research, I have decided to start treatment with Actermra this month. Like most insurances now in the U S, payment for this treatment was denied. With the physician's office, we are appealing the claim. Either way, I don't expect much financial reimbursement from the insurance and it is extremely costly. It is estimated over 10,000 dollars a year.
Fortunately, good news! I received approval today from the drug manufacturer in what they refer to as the "coverage and patient assistance program." Also known as Genenentech Access to Care Foundation. What this means is I will pay a 5.00 copay for each treatment. The insurance is than billed as the primary, and than the assistance program will be billed as the secondary and will cover my remaining balance up to 10,000 Dollars. I receive a card with the 10k balance which will be decremented with each treatment.
I not sure how long this offer will be open or how it works with the physician. I am going through Stanford so they provided me with the package to apply.
The results from the clinical trials seem better than what is currently available in regards to GCA treatments, so I am hopeful. Here is the phone number to call if you want more info. 1 855 722 6729.
Good luck and I will keep you posted on how it goes.
TJ